BioWorld

Aug. 11, 2008

Metabasis Gets $10M Up Front in Roche HepDirect Collaboration

Metabasis Therapeutics Inc. signed a $203 million research collaboration with F. Hoffmann La-Roche Ltd., resulting in some much-needed validation for its HepDirect liver-targeting technology as well as a boost to its stock price and cash balance. (BioWorld Today) Read More

Adipose Stem Cell Firm Cytori Adds $17M for Celution, Trials

Sense-Antisense Pair Feeds Each Other, Amyloid Plaques

New CDC Reports Shed Light on HIV Incidence and Testing

Scientists Create Specific Cell Lines for 10 Diseases

Earnings Roundup

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...